Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3Phase 1/2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NETWORK 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Leukemia 41Breast Neoplasms 28Lymphoma 21Leukemia, Myeloid, Acute 16Burkitt Lymphoma 13Myelodysplastic Syndromes 11Graft vs Host Disease 10Lymphoma, Non-Hodgkin 7Lymphoma, Large B-Cell, Diffuse 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Leukemia, Biphenotypic, Acute 7Squamous Cell Carcinoma of Head and Neck 6Urinary Bladder Neoplasms 5Leukemia, Promyelocytic, Acute 5Hodgkin Disease 5Anemia, Refractory, with Excess of Blasts 5Osteosarcoma 4Myeloproliferative Disorders 4Lymphoma, Follicular 4Leukemia, Myelomonocytic, Chronic 4Head and Neck Neoplasms 4Arthritis, Rheumatoid 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Lymphocytic, Chronic, B-Cell 3

Interventions

pegaspargase 3merphos 3dexamethasone acetate 3dexamethasone 21-phosphate 3azathiopurine 3auricularum 3Vincristine 3Thioguanine 3Methotrexate 3Mercaptopurine 3Leucovorin 3Doxorubicin 3Dexamethasone 3Cytarabine 3Cyclophosphamide 3Calcium Dobesilate 3prednylidene 2deltacortene 2blinatumomab 2Radiotherapy 2Radiation 2Prednisone 2Prednisolone 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Methylprednisolone 2Asparaginase 2calaspargase pegol 1asparaginase erwinia chrysanthemi recombinant 1Specimen Handling 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Precursor B-Cell Lymphoblastic Leukemia-Lymphoma × Methotrexate × Clear all
NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
6,720 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT01190930 2026-05-22

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

Children's Oncology Group

Phase 3 Completed
9,350 enrolled 51 charts
LymphoidOther hematologic neoplasm

Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03959085 2026-05-05

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

Phase 3 Recruiting
5,951 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡